Skip to main content

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients

Objective

To evaluate the differences in administered in a lipid emulsion compared to amphotericin B (AmpoB) in dextrose 5%, for the treatment of Candida albicans infection.

Sixty consecutive critically ill patients with confirmed or suspected Candida infection received AmphoB (1 mg/kg/24 h) administered randomly in either dextrose 5% (group A) or in lipid emulsion (20% Intralipid®) (group B).

Measurements and main results

Clinical tolerance (fever, chills, hemodynamics), liver function tests, electrolytes and coagulation profile were evaluated. Patients receiving AmphoB in lipid emulsion experienced a lower incidence of drug-associated fever (61.4% versus 5.8%, P < 0.003), rigors (54% versus 8.5%, P < 0.004), hypotension (17% versus 0%) and nephrotoxicity. Significant thrombocytopenia (264,500 ± 71,460/mm3 to 163,570 ± 34,450/mm3, P < 0.01), not associated with active bleeding, occurred with AmphoB-lipid emulsion but not with the dextrose regimen.

Conclusions

Treatment with AmphoB-lipid emulsion of critically ill patients with Candida infection seems to be safer and as effective as the conventional mode of administration.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sorkine, P., Nagar, H., Weinbroum, A. et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients. Crit Care 1, P040 (1997). https://doi.org/10.1186/cc46

Download citation

Keywords

  • Lipid
  • Liver Function
  • Thrombocytopenia
  • Emergency Medicine
  • Lower Incidence